Found 4 matching trials
Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia
N/ABackground. Hemophiliac arthropathy is the main long-term physical damage i...
Location
Universidad Europea de Madrid
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
PHASE1Sobi.BIVV001-003 is an open-label, 2-period, fixed sequence study for intra...
Location
Sobi Investigational Site
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
PHASE1Primary objective
• To assess the half-life of BIVV001, Standard Half-Life...
Location
Investigational Site Number :1000001
Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia
N/AIntroduction: Hemophilia is a congenital coagulopathy characterised by recu...
Location
Universidad de Oviedo